# John Wilding

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-wilding/

## Facts

| Field | Value |
| --- | --- |
| Citations | 57,626 |
| Field | Diabetes Treatment and Management |
| h-index | 95 |
| i10-index | 354 |
| Last Known Institution | University of Liverpool |
| OpenAlex ID | https://openalex.org/A5047195042 |
| ORCID iD | 0000-0003-2839-8404 |
| Works | 727 |

## Researcher papers

Showing 12 of 20.

- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Once-Weekly Semaglutide in Adults with Overweight or Obesity](https://scholariq.org/papers/once-weekly-semaglutide-in-adults-with-overweight-or-obesity/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management](https://scholariq.org/papers/a-randomized-controlled-trial-of-3-0-mg-of-liraglutide-in-weight-management/)
- [A role for glucagon-like peptide-1 in the central regulation of feeding](https://scholariq.org/papers/a-role-for-glucagon-like-peptide-1-in-the-central-regulation-of-feeding/)
- [Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation](https://scholariq.org/papers/obesity-a-chronic-relapsing-progressive-disease-process-a-position-statement-of/)
- [Definition and diagnostic criteria of clinical obesity](https://scholariq.org/papers/definition-and-diagnostic-criteria-of-clinical-obesity/)
- [Management of obesity](https://scholariq.org/papers/management-of-obesity/)
- [Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension](https://scholariq.org/papers/weight-regain-and-cardiometabolic-effects-after-withdrawal-of-semaglutide-the/)
- [Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin](https://scholariq.org/papers/effects-of-dapagliflozin-on-body-weight-total-fat-mass-and-regional-adipose/)
- [Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis](https://scholariq.org/papers/differentiation-of-diabetes-by-pathophysiology-natural-history-and-prognosis/)
- [Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-semaglutide-compared-with-liraglutide-and-placebo-for/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)
- [Regulation of Appetite and Obesity](https://scholariq.org/topics/regulation-of-appetite-and-obesity/)
- [Diet and metabolism studies](https://scholariq.org/topics/diet-and-metabolism-studies/)

## Researcher university

- [University of Liverpool](https://scholariq.org/institutions/university-of-liverpool/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.